Artigos

Search for articles

BJO Oncology - Placeholder

Uterine carcinosarcoma with microsatellite instability - does immunotherapy modify the therapeutic scenario? A case report and literature review

Andrade, Warne Pedro ID
,
Melo, Andreia C ID
,
Nogueira-Rodrigues, Angelica ID
,
Buzatto, Isabela Panzeri Carlotti ID
,
Wada, Danilo Tadao ID
,
Paulino, Eduardo ID
,
Andrade, Diocesio Alves Pinto ID
ABSTRACT Carcinosarcomas were reclassified by World Health Organization as high-grade uterine carcinomas in 2014. Due to its rare histology, comprising only 5% of uterine carcinomas, there is a small representation of this tumor in studies that evaluate metastatic uterine carcinomas treatment. In 2022, the treatment of metastatic uterine carcinomas has...
Read abstract
Complete article
Download article
BJO Oncology - Placeholder

PARP inhibitors as first-line maintenance therapy in ovarian cancer: recommendations from an expert panel from Brazil

Cronemberger, Eduardo ID
,
Assad, Daniele Xavier ID
,
Cossetti, Rachel ID
,
de-Azevedo, Carla Rameri ID
,
Calabrich, Aknar FC ID
,
Morelle, Alessandra Menezes ID
,
Melo, Andreia C ID
,
Nunes, João Soares ID
,
Nogueira-Rodrigues, Angelica ID
,
Maluf, Fernando C ID
,
Guindalini, Rodrigo ID
,
Crosara, Marcela ID
,
Dal-Molin, Graziela ID
,
Leite, Ana Carolina ID
,
Kalil, Karime ID
,
Paulino, Eduardo ID
,
Signorini, Poliana ID
,
de-Freitas, Daniela ID
,
Almeida, Michelle Samora ID
,
Guimarães, Andrea PG ID
ABSTRACT To report consensus recommendations on the current role of poly(ADP-ribose) polymerase (PARP) inhibitors in the front-line management of patients with epithelial ovarian cancer (EOC) in the healthcare setting of Brazil. The expert panel convened in March 2021 and comprised 20 medical oncologists focus on gynecological oncology. The panel answered...
Read abstract
Complete article
Download article